Skip to contentS
Sonoma Pharmaceuticals, Inc.
S
SNOASonoma Pharmaceuticals, Inc. Q3 2024 · 10-Q
Revenue$3.14M$3.14M+6.6% vs Q3 2023 Net Income-$866.00K-$866.00KN/M vs Q3 2023 EPS Diluted-$1.59-$1.59N/M vs Q3 2023 Gross Profit$1,460,000+75.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sonoma Pharmaceuticals, Inc. · CIK 1367083 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,104,000N/M Free Cash Flowderived-$1,105,000N/M Margins · derivedGross margin46.5%+18.3 pt vs Q3 2023
Operating margin-26.9%+35.4 pt vs Q3 2023
Net margin-27.6%+38.3 pt vs Q3 2023
ended Dec 31, 2023 · filed Feb 8, 2024 · 39 d after period end